AbbVie

AbbVie reports strong growth in immunology and neurology, which contributed to revenue and margin increases in the second quarter. The board raised its 2026 revenue forecast to $67.6 billion, but slightly narrowed the range for adjusted earnings per share because of the $10.9 billion Apogee acquisition. Management continues to emphasize financial flexibility for further acquisitions; investors are eyeing the nine-month results on October 30. » Więcej na finanzen.net

ADARx Pharmaceuticals plans a US IPO targeting a valuation up to $1.74 billion and aims to raise as much as $371.9 million by offering 21.9 million shares at $15–$17 each. AbbVie agreed to invest up to $100 million in a concurrent private placement, representing roughly a 4.9% stake post-IPO. ADARx, which develops RNA-based therapies with three programs in clinical testing and its lead candidate onvuzosiran in late-stage trials, will list on Nasdaq under the symbol ADRX with JPMorgan, Morgan Stanley and TD Cowen among the underwriters. » Więcej na finance.yahoo.com

Qulipta met the primary endpoint in a Phase 3 trial by significantly reducing perimenstrual migraine days versus placebo, hit all secondary endpoints and showed no new safety signals, supporting a likely label expansion. AbbVie estimates a U.S. addressable population of several million for menstrual migraine, though eventual uptake will depend on coverage, physician adoption and patient treatment choices. Qulipta generated $350 million in Q2 sales (up 31% YoY) and is forecast by some analysts to reach peak sales above $2 billion, but AbbVie’s main growth drivers remain Skyrizi and Rinvoq; the company also retains a strong dividend profile. » Więcej na finance.yahoo.com

AbbVie declared a $1.73 quarterly dividend payable Nov. 16 to holders of record on Oct. 15, maintaining the payout introduced earlier in 2026. The annualized $6.92 payment yields roughly 2.7% today, but the company’s long track record of dividend increases—over 330% since 2013 and a 5.5% raise most recently—remains the main attraction. AbbVie generated $7.27 billion in operating cash flow in H1 2026 and paid $6.2 billion in dividends over the period, supporting the payout but leaving limited excess cash amid acquisitions, buybacks and debt considerations that could slow future dividend growth. » Więcej na finance.yahoo.com

At the Morgan Stanley Healthcare Conference, AbbVie said it has offset Humira’s $18 billion revenue erosion with $28 billion in non‑Humira growth and is targeting a peak revenue that is about $10 billion above Humira’s high. Drivers are immunology and neuroscience; important near‑term catalysts include SKYRIZI (subcutaneous induction), new indications for RINVOQ, tavapadon and etentamig. The acquisition of Apogee brings zumilokibart for atopic dermatitis into late‑stage development, and AbbVie also sees long‑term potential in oncology and obesity. Management warned, however, of sustained biosimilar pressure, regulatory challenges and the need for further investment. » Więcej na de.investing.com